Tirzepatide
Description
Tirzepatide is a synthetic analogue of gastric inhibitory polypeptide (GlP) that wasdeveloped for its ability to stimulate insulin release and thus address both type 2 diabetesand non-alcoholic fatty liver disease. Made up of 39 amino acids, the relatively largeTirzepatide stimulates the release of insulin from the pancreas by binding to both GIP andGLP-1 (glucagon-like peptide-1)receptors. Taken over longer periods of time, Tirzepatideincreases adiponectin levels by as much as 26% as well[1].
Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ (C20 fattyacid)AFVQWLIAGGPSSGAPPPS
Note: Aib is a non-coded (non-proteinogenic) amino acid – HzH-C(CH3)2-COOH
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.527 g/mol
PubChem ClD: 156588324
CAS Number: 2023788-19-2
Synonyms: P1206,LY3298176
Additional Information
| Tirzepatide Size | 100mg/vial*10 vials, 10mg/vial*10 vials, 110mg/vial*10 vials, 120mg/vial*10 vials, 15mg/vial*10 vials, 20mg/vial*10 vials, 25mg/vial*10 vials, 2mg/vial*10 vials, 30mg/vial*10 vials, 40mg/vial*10 vials, 50mg/vial*10 vials, 5mg/vial*10 vials, 60mg/vial*10 vials, 70mg/vial*10 vials, 80mg/vial*10 vials, 90mg/vial*10 vials |
|---|
